NVO:NYSE
Novo Nordisk A/S
$46.60
arrow_downward
-1.92%(-0.91) 1D
$46.50
arrow_downward
-0.21% (-0.100)bedtimeAfter hours
Closed: Sep 4, 4:00:08 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVO...
Open
$46.35
High
$46.74
Low
$46.04
Mkt. cap
155.46B
Avg. vol.
13.01M
Volume
6.22M
Dividend
3.86%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
11.48
52-wk high
$64.16
52-wk low
$35.12
EPS
$4.06
Beta
0.73
Shares outstanding
3.39B
No. of employees
67K
Open
$46.35
High
$46.74
Low
$46.04
Mkt. cap
155.46B
Avg. vol.
13.01M
Volume
6.22M
Dividend
3.86%
Quarterly dividend
$0.45
Ex-dividend date
Aug 14, 2026
P/E ratio
11.48
52-wk high
$64.16
52-wk low
$35.12
EPS
$4.06
Beta
0.73
Shares outstanding
3.39B
No. of employees
67K
News stories
From web sources and news partners
News Corp
·
6 hours ago
Plastic surgery is booming with boomers. Here’s how to cash in on the antiaging craze.
Simply Wall Street
·
12 hours ago
Novo Nordisk (NVO) Stock May Be Below Fair Value After GLP 1 Legal News
Yahoo Finance
·
23 hours ago
Novo Nordisk (CPSE:NOVO B) Stock Looks Below Fair Value But Faces Earnings Doubts
Profile
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices.
Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company in Denmark. Wikipedia
About Novo Nordisk A/S
CEOMaziar Mike Doustdar
Employees66.7K
FoundedDec 21, 1923
HeadquartersBagsværd, Capital Region of Denmark, Denmark
SectorPharmaceutical industry
Websitenovonordisk.com